🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal

RecruitingPhase 2Ages 18 Years - 80 YearsAllUniversity of Calgary
NCT04939623 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The proposed clinical trial will address the problem of opioid withdrawal. Opioids are essential for pain-relief in the short term, but their continued use is associated with a host of adverse effects. People living with chronic pain who were initiated on opioid therapy now find themselves with a major life-changing problem - dependence on opioid medications. Opioid withdrawal symptoms are a key barrier to decreasing or stopping their opioid medication. Currently, there are few medications that ameliorate the symptoms of opioid withdrawal. This problem is a major part of the opioid crisis in Canada, and impacts people across all demographics and socioeconomic status. A misconception is that only individuals with opioid use disorder are susceptible to opioid withdrawal; on the contrary, appropriate use of prescription opioids to manage pain can lead to significant symptoms of opioid withd

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment. 2. Subjects are currently taking a daily opioid pain medication and planning to taper the dose. 3. Participants complete at least one voluntary opioid dose reduction in the twelve-week study period. 4. Glomerular filtration rate (GFR) \> 50 mL/min 5. Capable of providing informed consent Exclusion Criteria: 1. Allergy to probenecid or related drugs 2. History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi. 3. Known G6PD deficiency 4. Active gout in any joint 5. Current use of drugs whose exposure may be prolonged, or risk of toxicity increased when used in combination with probenecid: 1. Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin 2. Carbapenems, specifically doripenem and meropenem 3. Lorazepam, midazolam, nitrazepam 4. Ketorolac 5. Oseltamivir 6. Methotrexate 7. Mycophenolate 6. Current use of drugs which may mask symptoms of withdrawal: a. Clonidine, lofexidine, tizanidine 7. Current use of drugs which may diminish the effect of probenecid: a. High dose salicylates including greater than 325 mg PO daily of acetylsalicylic acid (ASA) 8. Pregnancy or breastfeeding 9. Any major comorbid medical condition which might impair follow-up or result in a safety risk to the participant 10. Participation in another clinical trial investigating a drug, medical device, or a medical procedure during the 30 days prior to enrolment. \-
💊

What it tests

  • Probenecid
📍

Where

1 site
Richmond Road Diagnostic and Treatment Centre
Calgary, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy